Arbutus biopharma, x-chem and proteros biostructures achieve first milestone under covid-19 discovery research and license agreement

screening identifies several unique compound series that inhibit the sars-cov-2 nsp5 main protease, a validated target for the treatment of covid-19 and potential future coronavirus outbreaks
ABUS Ratings Summary
ABUS Quant Ranking